The landscape of Mucopolysaccharidosis in Southern and Eastern European countries: a survey from 19 specialistic centers.
Enzyme replacement therapy
Morquio A syndrome
Mucopolysaccharidoses
Southern and Eastern European countries
Treatment accessibility
Journal
Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602
Informations de publication
Date de publication:
24 03 2022
24 03 2022
Historique:
received:
15
11
2021
accepted:
13
03
2022
entrez:
25
3
2022
pubmed:
26
3
2022
medline:
14
4
2022
Statut:
epublish
Résumé
Mucopolysaccharidoses (MPS) are a group of lysosomal storage disorders caused by defects in genes coding for different lysosomal enzymes which degrade glycosaminoglycans. Impaired lysosomal degradation causes cell dysfunction leading to progressive multiorgan involvement, disabling consequences and poor life expectancy. Enzyme replacement therapy (ERT) is now available for most MPS types, offering beneficial effects on disease progression and improving quality of life of patients. The landscape of MPS in Europe is not completely described and studies on availability of treatment show that ERT is not adequately implemented, particularly in Southern and Eastern Europe. In this study we performed a survey analysis in main specialist centers in Southern and Eastern European countries, to outline the picture of disease management in the region and understand ERT implementation. Since the considerable number of MPS IVA patients in the region, particularly adults, the study mainly focused on MPS IVA management and treatment. 19 experts from 14 Southern and Eastern European countries in total responded to the survey. Results outlined a picture of MPS management in the region, with a high number of MPS patients managed in the centers and a high level of care. MPS II was the most prevalent followed by MPS IVA, with a particular high number of adult patients. The study particularly focused on management and treatment of MPS IVA patients. Adherence to current European Guidelines for follow-up of MPS IVA patients is generally adequate, although some important assessments are reported as difficult due to the lack of MPS skilled specialists. Availability of ERT in Southern and Eastern European countries is generally in line with other European regions, even though regulatory, organizational and reimbursement constrains are demanding. The landscape of MPS in Southern and Eastern European countries is generally comparable to that of other European regions, regarding epidemiology, treatment accessibility and follow up difficulties. However, issues limiting ERT availability and reimbursement should be simplified, to start treatment as early as possible and make it available for more patients. Besides, educational programs dedicated to specialists should be implemented, particularly for pediatricians, clinical geneticists, surgeons, anesthesiologists and neurologists.
Sections du résumé
BACKGROUND
Mucopolysaccharidoses (MPS) are a group of lysosomal storage disorders caused by defects in genes coding for different lysosomal enzymes which degrade glycosaminoglycans. Impaired lysosomal degradation causes cell dysfunction leading to progressive multiorgan involvement, disabling consequences and poor life expectancy. Enzyme replacement therapy (ERT) is now available for most MPS types, offering beneficial effects on disease progression and improving quality of life of patients. The landscape of MPS in Europe is not completely described and studies on availability of treatment show that ERT is not adequately implemented, particularly in Southern and Eastern Europe. In this study we performed a survey analysis in main specialist centers in Southern and Eastern European countries, to outline the picture of disease management in the region and understand ERT implementation. Since the considerable number of MPS IVA patients in the region, particularly adults, the study mainly focused on MPS IVA management and treatment.
RESULTS
19 experts from 14 Southern and Eastern European countries in total responded to the survey. Results outlined a picture of MPS management in the region, with a high number of MPS patients managed in the centers and a high level of care. MPS II was the most prevalent followed by MPS IVA, with a particular high number of adult patients. The study particularly focused on management and treatment of MPS IVA patients. Adherence to current European Guidelines for follow-up of MPS IVA patients is generally adequate, although some important assessments are reported as difficult due to the lack of MPS skilled specialists. Availability of ERT in Southern and Eastern European countries is generally in line with other European regions, even though regulatory, organizational and reimbursement constrains are demanding.
CONCLUSIONS
The landscape of MPS in Southern and Eastern European countries is generally comparable to that of other European regions, regarding epidemiology, treatment accessibility and follow up difficulties. However, issues limiting ERT availability and reimbursement should be simplified, to start treatment as early as possible and make it available for more patients. Besides, educational programs dedicated to specialists should be implemented, particularly for pediatricians, clinical geneticists, surgeons, anesthesiologists and neurologists.
Identifiants
pubmed: 35331284
doi: 10.1186/s13023-022-02285-x
pii: 10.1186/s13023-022-02285-x
pmc: PMC8943501
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
136Informations de copyright
© 2022. The Author(s).
Références
Expert Rev Clin Pharmacol. 2016 Dec;9(12):1521-1532
pubmed: 27855521
Methods Enzymol. 1982;83:559-72
pubmed: 6808304
Am J Med Genet A. 2015 Jan;167A(1):11-25
pubmed: 25346323
Hum Mutat. 2014 Nov;35(11):1271-9
pubmed: 25137622
Eur J Intern Med. 2016 Oct;34:2-10
pubmed: 27296591
Mol Genet Metab. 2016 Sep;119(1-2):131-43
pubmed: 27380995
Orphanet J Rare Dis. 2021 May 29;16(1):241
pubmed: 34051828
J Inherit Metab Dis. 2014 Nov;37(6):979-90
pubmed: 24810369
BioDrugs. 2014 Oct;28(5):465-75
pubmed: 25200032
Int J Mol Sci. 2020 Feb 23;21(4):
pubmed: 32102177
Semin Pediatr Neurol. 2021 Apr;37:100874
pubmed: 33892850
N Engl J Med. 1991 May 23;324(21):1464-70
pubmed: 2023606
Orphanet J Rare Dis. 2017 May 23;12(1):98
pubmed: 28535791
Front Med (Lausanne). 2021 Feb 25;8:652358
pubmed: 33738294
Lancet. 2018 Sep 1;392(10149):791-794
pubmed: 30037734
J Inherit Metab Dis. 2007 Apr;30(2):165-74
pubmed: 17347914
Curr Pharm Biotechnol. 2011 Jun;12(6):931-45
pubmed: 21506915
Orphanet J Rare Dis. 2021 Jan 21;16(1):38
pubmed: 33478511
Rheumatology (Oxford). 2011 Dec;50 Suppl 5:v4-12
pubmed: 22210669
Intractable Rare Dis Res. 2020 Feb;9(1):1-9
pubmed: 32201668
Orphanet J Rare Dis. 2019 Jun 13;14(1):137
pubmed: 31196221
Orphanet J Rare Dis. 2020 May 14;15(1):114
pubmed: 32410642
Mol Genet Metab. 2013 May;109(1):54-61
pubmed: 23452954
Ital J Pediatr. 2018 Nov 16;44(Suppl 2):120
pubmed: 30442189
JIMD Rep. 2015;15:59-66
pubmed: 24718838
Acta Paediatr. 2008 Nov;97(11):1577-81
pubmed: 18681890
Orphanet J Rare Dis. 2020 Jan 6;15(1):3
pubmed: 31907071
Mol Genet Metab. 2014 Feb;111(2):63-72
pubmed: 24388732
Res Rep Endocr Disord. 2012 Dec;2012(2):65-77
pubmed: 24839594
Orphanet J Rare Dis. 2020 Dec 3;15(1):341
pubmed: 33272301
Lancet. 1981 Oct 3;2(8249):709-12
pubmed: 6116856
Int J Mol Sci. 2020 Apr 23;21(8):
pubmed: 32340185
Mol Genet Metab Rep. 2019 Oct 21;21:100508
pubmed: 31687335